The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study
Journal of Clinical Lipidology · 2025
DOI: 10.1016/j.jacl.2025.01.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2025. Verfasst von Da Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China (Drs Zhou, Song, Han, Zhang, Ji, Meng); Advanced Center of Strok…. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Intracranial Aneurysm, Hypolipidemic Agents. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Observational studies have suggested potential correlations between unfavorable lipid profiles and the occurrence of intracranial aneurysms (IAs), proposing that lipid-lowering therapies might curb IA progression and prevent rupture. This study aimed to explore the causal impacts of lipid-reducing strategies on the risk of IAs. METHODS: We employed 3 genetic tools as proxies for our exposures and assessed causal effects using outcome genome-wide association study data from the FinnGen Biobank. Single nucleotide polymorphisms strongly associated with low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol, and triglycerides, located within ±100 kb of the region of target genes, were selected as instrumental variables for drug-target Mendelian randomization (MR). Additionally, gene expression and protein MR analyses were conducted to elucidate the causal effects of lipid levels from transcriptional and translational perspectives, using two-sample MR (TSMR) and summary-data-based MR (SMR). RESULTS: Drug-target MR analysis revealed that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition-mediated LDL-C reduction was associated with an increased risk of IA development (odds ratio [OR] = 1.406, P = 3.28E-09). In contrast, protein MR demonstrated that higher PCSK9 expression had protective effects against IA incidence (ORTSMR = 0.896, P = 1.79E-03; ORSMR = 0.881, P = 1.78E-02). Subgroup analyses further suggested that PCSK9 might reduce the risk of IA rupture (ORTSMR = 0.893, P = 1.08E-02; ORSMR = 0.866, P = 3.39E-02). CONCLUSION: Our MR analyses indicated a potential causal relationship between higher PCSK9 expression and a reduced risk of both IA formation and rupture, highlighting the dual role of PCSK9 inhibitors in cerebrovascular disease. Hence, careful consideration is warranted when prescribing PCSK9 inhibitors, particularly in patients at risk for developing IAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China (Drs Zhou, Song, Han, Zhang, Ji, Meng); Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China (Drs Zhou, So…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhou, D., Song, J., Han, G., Zhang, X., Ji, X., & Meng, R. (2025). The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2025.01.003
Vancouver
Zhou D, Song J, Han G, Zhang X, Ji X, Meng R. The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study. Journal of Clinical Lipidology. 2025. doi:10.1016/j.jacl.2025.01.003
BibTeX
@article{Zhou2025,
author = {Zhou, Da and Song, Jiahao and Han, Guangyu and Zhang, Xiaoming and Ji, Xunming and Meng, Ran},
title = {The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study},
journal = {Journal of Clinical Lipidology},
year = {2025},
doi = {10.1016/j.jacl.2025.01.003}
}
EUVIMED